• Pleinlaan 2

    1050 Brussels


Find us here

Organization profile

Organisation profile

A decreased beta cell mass or the incapability of the beta cell mass to compensate for increased insulin needs, results in an absolute or relative deficiency of insulin defining type I and type II diabetes, respectively. Our research group aims to compensate the reduced beta cell mass in diabetes by transplantation or in situ differentiation and expansion of beta- and pre-beta cells. We therefore investigate mechanisms to generate new, fully functional beta cells by: - Differentiation of endogenous progenitor/stem cells - regeneration of the beta cell mass - Protection and profileration of existing beta cells - Transdifferentiation of pancreatic non-beta cells to beta cells Our research is performed within the collaborative framework of the JDRF Center for Beta Cell Therapy in Diabetes and the Beta Cell Biology Consortium.


Dive into the research topics where Beta Cell Neogenesis is active. These topic labels come from the works of this organisation's members. Together they form a unique fingerprint.


Recent external collaboration on country level. Dive into details by clicking on the dots or